Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France

Given current meningococcal epidemiology in France and the available data on the protection provided by Bexsero®, our modelling work showed that routine vaccination against serogroup B meningococcal disease is not cost-effective.